Details of the Drug

General Information of Drug (ID: DM5IKUF)

Drug Name
Dihydroergotamine
Synonyms Migranal (TN)
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1]
Therapeutic Class
Antimigraine Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 583.7
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.4-4 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The renal clearance of drug is 0.1 L/h [4]
Elimination
6-7% of a single intramuscular dose is excreted in the urine [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.7 - 1 hour [5]
Metabolism
The drug is metabolized via the liver [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0734 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.07% [7]
Vd
The volume of distribution (Vd) of drug is 800 L [4]
Chemical Identifiers
Formula
C33H37N5O5
IUPAC Name
(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES
C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
InChI
InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
InChIKey
LUZRJRNZXALNLM-JGRZULCMSA-N
Cross-matching ID
PubChem CID
10531
ChEBI ID
CHEBI:4562
CAS Number
511-12-6
DrugBank ID
DB00320
TTD ID
D0V3ZA
VARIDT ID
DR00686
INTEDE ID
DR0504
ACDINA ID
D00199

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Migraine
ICD Disease Classification 8A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dihydroergotamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Dihydroergotamine caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [29]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Dihydroergotamine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Arn-509 DMT81LZ Moderate Increased metabolism of Dihydroergotamine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Mitotane DMU1GX0 Moderate Increased metabolism of Dihydroergotamine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [29]
Epinephrine DM3KJBC Major Additive hypertensive effects by the combination of Dihydroergotamine and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [30]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Dihydroergotamine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [31]
Nifedipine DMSVOZT Moderate Decreased metabolism of Dihydroergotamine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [31]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Dihydroergotamine and Buspirone. Anxiety disorder [6B00-6B0Z] [32]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Dihydroergotamine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [29]
Voriconazole DMAOL2S Major Decreased metabolism of Dihydroergotamine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [31]
Posaconazole DMUL5EW Major Decreased metabolism of Dihydroergotamine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [31]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Dihydroergotamine caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [31]
Ephedrine DMMV0KW Major Additive hypertensive effects by the combination of Dihydroergotamine and Ephedrine. Asthma [CA23] [30]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Dihydroergotamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [32]
Oritavancin DM28D05 Moderate Increased metabolism of Dihydroergotamine caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Dihydroergotamine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dihydroergotamine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [33]
Clarithromycin DM4M1SG Major Decreased metabolism of Dihydroergotamine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Dihydroergotamine caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Troleandomycin DMUZNIG Major Decreased metabolism of Dihydroergotamine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Erdafitinib DMI782S Moderate Increased metabolism of Dihydroergotamine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [34]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Dihydroergotamine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [29]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Dihydroergotamine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Tucatinib DMBESUA Major Decreased metabolism of Dihydroergotamine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dihydroergotamine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Pseudoephedrine DMIVJ0D Major Additive hypertensive effects by the combination of Dihydroergotamine and Pseudoephedrine. Breathing abnormality [MD11] [30]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Dihydroergotamine caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [31]
Secobarbital DM14RF5 Moderate Increased metabolism of Dihydroergotamine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [29]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Dihydroergotamine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [29]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Dihydroergotamine and Levomilnacipran. Chronic pain [MG30] [32]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Dihydroergotamine and Alfentanil. Corneal disease [9A76-9A78] [32]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Dihydroergotamine and Remifentanil. Corneal disease [9A76-9A78] [32]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Dihydroergotamine and Dextromethorphan. Cough [MD12] [32]
Mifepristone DMGZQEF Major Decreased metabolism of Dihydroergotamine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [35]
Pasireotide DMHM7JS Moderate Decreased metabolism of Dihydroergotamine caused by Pasireotide mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Dihydroergotamine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Dihydroergotamine caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [29]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Dihydroergotamine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [29]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Dihydroergotamine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [31]
MK-8228 DMOB58Q Major Decreased metabolism of Dihydroergotamine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Dihydroergotamine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Dihydroergotamine and Sertraline. Depression [6A70-6A7Z] [32]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Dihydroergotamine and Trimipramine. Depression [6A70-6A7Z] [32]
Imipramine DM2NUH3 Major Additive serotonergic effects by the combination of Dihydroergotamine and Imipramine. Depression [6A70-6A7Z] [32]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Dihydroergotamine and Fluoxetine. Depression [6A70-6A7Z] [32]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Dihydroergotamine and Nortriptyline. Depression [6A70-6A7Z] [32]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Dihydroergotamine and Vilazodone. Depression [6A70-6A7Z] [32]
Nefazodone DM4ZS8M Major Decreased metabolism of Dihydroergotamine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Dihydroergotamine and Paroxetine. Depression [6A70-6A7Z] [32]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Dihydroergotamine and Selegiline. Depression [6A70-6A7Z] [36]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Dihydroergotamine and Vortioxetine. Depression [6A70-6A7Z] [32]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Dihydroergotamine and Duloxetine. Depression [6A70-6A7Z] [32]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Dihydroergotamine and Isocarboxazid. Depression [6A70-6A7Z] [36]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Dihydroergotamine and Milnacipran. Depression [6A70-6A7Z] [32]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Dihydroergotamine and Escitalopram. Depression [6A70-6A7Z] [32]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Dihydroergotamine and Tranylcypromine. Depression [6A70-6A7Z] [36]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Dihydroergotamine and Desvenlafaxine. Depression [6A70-6A7Z] [32]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Dihydroergotamine and Phenelzine. Depression [6A70-6A7Z] [36]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Dihydroergotamine and Trazodone. Depression [6A70-6A7Z] [32]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Dihydroergotamine and Amoxapine. Depression [6A70-6A7Z] [32]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Dihydroergotamine and Mirtazapine. Depression [6A70-6A7Z] [32]
Protriptyline DMNHTZI Major Additive serotonergic effects by the combination of Dihydroergotamine and Protriptyline. Depression [6A70-6A7Z] [32]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Dihydroergotamine and Doxepin. Depression [6A70-6A7Z] [37]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Dihydroergotamine and Maprotiline. Depression [6A70-6A7Z] [32]
Griseofulvin DMK54YG Moderate Increased metabolism of Dihydroergotamine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [29]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Dihydroergotamine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [37]
LEVONORDEFRIN DMWDJ0H Major Additive hypertensive effects by the combination of Dihydroergotamine and LEVONORDEFRIN. Discovery agent [N.A.] [30]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Dihydroergotamine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [32]
Primidone DM0WX6I Moderate Increased metabolism of Dihydroergotamine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Felbamate DM1V5ZS Moderate Increased metabolism of Dihydroergotamine caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Dihydroergotamine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Cenobamate DMGOVHA Moderate Increased metabolism of Dihydroergotamine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Dihydroergotamine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Rufinamide DMWE60C Moderate Increased metabolism of Dihydroergotamine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Phenobarbital DMXZOCG Moderate Increased metabolism of Dihydroergotamine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Carbamazepine DMZOLBI Moderate Increased metabolism of Dihydroergotamine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Dihydroergotamine caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Dihydroergotamine and Mephentermine. Essential hypertension [BA00] [30]
Oxymetazoline DM8ZXT6 Major Additive hypertensive effects by the combination of Dihydroergotamine and Oxymetazoline. Eyelid inflammatory disorder [9A02] [30]
Phenylephrine DMZHUO5 Major Additive hypertensive effects by the combination of Dihydroergotamine and Phenylephrine. Faecal incontinence [ME07] [30]
Tazemetostat DMWP1BH Moderate Increased metabolism of Dihydroergotamine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [29]
Itraconazole DMCR1MV Major Decreased metabolism of Dihydroergotamine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Miconazole DMPMYE8 Moderate Decreased metabolism of Dihydroergotamine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Ketoconazole DMPZI3Q Major Decreased metabolism of Dihydroergotamine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Dipivefrin DMH5W0G Major Additive hypertensive effects by the combination of Dihydroergotamine and Dipivefrin. Glaucoma [9C61] [30]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Dihydroergotamine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [29]
Boceprevir DMBSHMF Major Decreased metabolism of Dihydroergotamine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [38]
Telaprevir DMMRV29 Major Decreased metabolism of Dihydroergotamine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [38]
Tetrahydrozoline DMT57WC Major Additive hypertensive effects by the combination of Dihydroergotamine and Tetrahydrozoline. Herpes simplex infection [1F00] [30]
Rifampin DMA8J1G Moderate Increased metabolism of Dihydroergotamine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Rifapentine DMCHV4I Moderate Increased metabolism of Dihydroergotamine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Dihydroergotamine and Procarbazine. Hodgkin lymphoma [2B30] [36]
MK-1439 DM215WE Moderate Increased metabolism of Dihydroergotamine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Delavirdine DM3NF5G Major Decreased metabolism of Dihydroergotamine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Dihydroergotamine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Cobicistat DM6L4H2 Major Decreased metabolism of Dihydroergotamine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Efavirenz DMC0GSJ Major Decreased metabolism of Dihydroergotamine caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Saquinavir DMG814N Major Decreased metabolism of Dihydroergotamine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Etravirine DMGV8QU Moderate Increased metabolism of Dihydroergotamine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Amprenavir DMLMXE0 Major Decreased metabolism of Dihydroergotamine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Darunavir DMN3GCH Major Decreased metabolism of Dihydroergotamine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Atazanavir DMSYRBX Major Decreased metabolism of Dihydroergotamine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Ritonavir DMU764S Major Decreased metabolism of Dihydroergotamine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Levamlodipine DM92S6N Moderate Decreased metabolism of Dihydroergotamine caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Dihydroergotamine caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Amlodipine DMBDAZV Moderate Decreased metabolism of Dihydroergotamine caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Methoxamine DMF5XQH Major Additive hypertensive effects by the combination of Dihydroergotamine and Methoxamine. Hypertension [BA00-BA04] [30]
Metaraminol DMWIX23 Major Additive hypertensive effects by the combination of Dihydroergotamine and Metaraminol. Hypotension [BA20-BA21] [30]
Retapamulin DM9JXB7 Minor Decreased metabolism of Dihydroergotamine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [40]
Lesinurad DMUR64T Moderate Increased metabolism of Dihydroergotamine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [29]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Dihydroergotamine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [31]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Dihydroergotamine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Amobarbital DM0GQ8N Moderate Increased metabolism of Dihydroergotamine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [29]
Naphazoline DMJFZDL Major Additive hypertensive effects by the combination of Dihydroergotamine and Naphazoline. Itching [1F28-1G07] [30]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Dihydroergotamine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [29]
Crizotinib DM4F29C Moderate Decreased metabolism of Dihydroergotamine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Brigatinib DM7W94S Moderate Increased metabolism of Dihydroergotamine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [29]
Ceritinib DMB920Z Major Decreased metabolism of Dihydroergotamine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
PF-06463922 DMKM7EW Moderate Increased metabolism of Dihydroergotamine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [41]
Osimertinib DMRJLAT Moderate Increased metabolism of Dihydroergotamine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Moderate Decreased metabolism of Dihydroergotamine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Idelalisib DM602WT Major Decreased metabolism of Dihydroergotamine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
IPI-145 DMWA24P Moderate Decreased metabolism of Dihydroergotamine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
Vemurafenib DM62UG5 Moderate Increased metabolism of Dihydroergotamine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [29]
LGX818 DMNQXV8 Moderate Increased metabolism of Dihydroergotamine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [43]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dihydroergotamine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [42]
Danazol DML8KTN Moderate Decreased metabolism of Dihydroergotamine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [31]
Exjade DMHPRWG Moderate Increased metabolism of Dihydroergotamine caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [29]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Dihydroergotamine and Ozanimod. Multiple sclerosis [8A40] [36]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dihydroergotamine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Nilotinib DM7HXWT Moderate Decreased metabolism of Dihydroergotamine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Imatinib DM7RJXL Moderate Decreased metabolism of Dihydroergotamine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Dasatinib DMJV2EK Moderate Decreased metabolism of Dihydroergotamine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Modafinil DMYILBE Moderate Increased metabolism of Dihydroergotamine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [29]
Netupitant DMEKAYI Moderate Decreased metabolism of Dihydroergotamine caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [33]
Entrectinib DMMPTLH Moderate Decreased metabolism of Dihydroergotamine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [31]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Dihydroergotamine and Sibutramine. Obesity [5B80-5B81] [44]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Dihydroergotamine and Dexfenfluramine. Obesity [5B80-5B81] [32]
Propylhexedrine DMTBW2O Major Additive hypertensive effects by the combination of Dihydroergotamine and Propylhexedrine. Obesity [5B80-5B81] [30]
Phenylpropanolamine DMTFK3O Major Additive hypertensive effects by the combination of Dihydroergotamine and Phenylpropanolamine. Obesity [5B80-5B81] [30]
Olaparib DM8QB1D Moderate Decreased metabolism of Dihydroergotamine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [29]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Dihydroergotamine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [31]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Dihydroergotamine and Pentazocine. Pain [MG30-MG3Z] [32]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Dihydroergotamine and Meperidine. Pain [MG30-MG3Z] [32]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Dihydroergotamine and Safinamide. Parkinsonism [8A00] [36]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Dihydroergotamine and Rasagiline. Parkinsonism [8A00] [36]
Dopamine DMPGUCF Major Additive hypertensive effects by the combination of Dihydroergotamine and Dopamine. Parkinsonism [8A00] [30]
Abametapir DM2RX0I Moderate Decreased metabolism of Dihydroergotamine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [45]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Dihydroergotamine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [31]
Lefamulin DME6G97 Moderate Decreased metabolism of Dihydroergotamine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [46]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Dihydroergotamine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [31]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Dihydroergotamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [31]
Enzalutamide DMGL19D Moderate Increased metabolism of Dihydroergotamine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [29]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Dihydroergotamine caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [31]
Bosentan DMIOGBU Moderate Increased metabolism of Dihydroergotamine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [29]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Dihydroergotamine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [47]
Dexamethasone DMMWZET Moderate Increased metabolism of Dihydroergotamine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [29]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Dihydroergotamine and Fentanyl. Sensation disturbance [MB40] [32]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Dihydroergotamine and Sufentanil. Sensation disturbance [MB40] [32]
Norepinephrine DMOUC09 Major Additive hypertensive effects by the combination of Dihydroergotamine and Norepinephrine. Sepsis [1G40-1G41] [30]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dihydroergotamine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [31]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dihydroergotamine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [29]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dihydroergotamine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Armodafinil DMGB035 Moderate Increased metabolism of Dihydroergotamine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Pitolisant DM8RFNJ Moderate Increased metabolism of Dihydroergotamine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [29]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dihydroergotamine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [48]
Brilinta DMBR01X Moderate Decreased metabolism of Dihydroergotamine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [42]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Dihydroergotamine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [47]
Elagolix DMB2C0E Moderate Increased metabolism of Dihydroergotamine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [29]
Xylometazoline DMKV32D Major Additive hypertensive effects by the combination of Dihydroergotamine and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [30]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Dihydroergotamine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [31]
⏷ Show the Full List of 171 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dihydroergotamine 1 mg tablet 1 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
2 FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 FDA Approved Drug Products: TRUDHESA (dihydroergotamine mesylate) nasal spray
5 Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
9 CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
20 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
21 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
22 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
23 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
25 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
26 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
27 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
28 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
29 Cerner Multum, Inc. "Australian Product Information.".
30 Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
31 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
32 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
33 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
34 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
35 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
36 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
37 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
38 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
39 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
40 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
41 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
44 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
45 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
46 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
48 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.